Novel Multikinase Inhibitor Gets Fast Track Status for Cholangiocarcinoma
The designation is based on results from a phase 1 study that evaluated TT-00420 at different dose levels in 9 CCA patients.
The designation is based on results from a phase 1 study that evaluated TT-00420 at different dose levels in 9 CCA patients.